Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Sarcoma is a rare cancer with poor outcomes.
• Histone deacetylase inhibitors (HDACi) like Panobinostat (LBH589) show anti-tumor effects in sarcoma.
• The precise mechanisms of LBH589 in sarcoma are not fully understood.

Purpose of the Study:

• To investigate the anti-tumor mechanisms of LBH589 in soft tissue sarcoma (STS).
• To explore the role of LBH589 in natural killer (NK) cell-mediated cytotoxicity.
• To elucidate the involvement of the Wnt/β-catenin pathway in LBH589's effects.

Main Methods:

• Cell proliferation and colony formation assays using STS cell lines.
• Transcriptome analysis to identify molecular changes induced by LBH589.
• Quantitative real-time PCR and flow cytometry to assess gene and protein expression (NKG2D ligands).
• In vitro co-culture and in vivo animal models to evaluate NK cell cytotoxicity.
• Wnt/β-catenin pathway inhibition studies.

Main Results:

• LBH589 inhibited STS cell proliferation and colony formation.
• LBH589 treatment upregulated the expression of NKG2D ligands (MICA/MICB).
• LBH589 activated the Wnt/β-catenin pathway via increased histone acetylation.
• LBH589 enhanced NK cell cytotoxicity, an effect reversed by Wnt/β-catenin inhibition.

Conclusions:

• LBH589 demonstrates anti-sarcoma activity by enhancing NK cell-mediated cytotoxicity.
• The Wnt/β-catenin pathway is a key mediator of LBH589's effects on NK cells.
• LBH589 shows potential as an adjunct therapy in NK cell-based immunotherapies for sarcoma.